Aurora Cannabis Inc. (NASDAQ:ACB) recently reported strong quarterly earnings that outpaced market expectations, despite a downturn across the cannabis sector.
Aurora's share price fell 18% following the earnings report, reflecting broader sector pressures, with the MSOS ETF down 29%. As of this morning, November 7, 2024, Aurora's stock is trading at $5.25 in pre-market, showing a 2.54% increase from its previous close.
"Despite having no U.S. exposure, Aurora surpassed consensus estimates on sales and EBITDA, encouraging guidance for the December quarter," observed analyst Pablo Zuanic of Zuanic & Associates.
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. You can't afford to miss out if you're serious about the business.
International Medical Cannabis Growth Drives Revenue
Aurora's international medical cannabis (MMJ) business significantly bolstered its revenue, with European sales doubling quarter-over-quarter to $20 million, led by strong demand in Germany and Poland.
Australian MMJ sales also rose from $9.3 million to $15.1 million, benefiting from an August inventory drawdown following the MedReleaf Australia acquisition.
Profit Margins Reflect International Expansion
The company's profitability has improved as higher-margin international markets now make up 57% of Aurora's global MMJ sales from 42% a year ago. This boosted adjusted cash gross margins to 68% for MMJ products, a 5% increase year-over-year, with total company margins rising 450 basis points to over 55%.
Operating expenses remained steady at $35 million per quarter, resulting in an EBITDA margin increase from 5% to 12% year-over-year.
Read Also: Cannabis Stocks Collapse After Trump Win: Major Players See Double-Digit Declines At Wednesday's Close
December Quarter Guidance And Challenges
Aurora anticipates stable sales and EBITDA for the December quarter, exceeding consensus by 9% and 90%, respectively. The outlook includes a seasonal decline in its propagation business but projects positive EBITDA and free cash flow, supported by Aurora's net cash position of $27 million (cash of $85 million against $58 million in Bevo-related debt).
Zuanic noted that international growth remains promising, although "shipments can be inconsistent, making end-market growth predictions difficult."
Valuation Compared To Peers
According to Zuanic, with a valuation of 1.4x its annualized sales, Aurora appears undervalued compared to competitors Tilray (NASDAQ:TLRY) and Canopy Growth (NASDAQ:CGC), which trade at multiples of 3-4x sales.
"Though business models differ, operational trends and lower valuation offer potential upside for ACB shares," Zuanic commented. Aurora's combination of higher-margin international revenue and more conservative valuation may present an opportunity amid sector volatility.
